Correlation between MRI & biopsies under second look Ultrasound

Similar documents
TÍTULO The role of FUSION between MRI and PET-CT as preoperative staging in breast cancer

Tips and Tricks to performing Magnetic Resonance Imaging Guided Breast Interventional Procedures Habib Rahbar, MD, FSBI October 23, 2018, 7:00pm ET

National Diagnostic Imaging Symposium 2013 SAM - Breast MRI 1

Is Probably Benign Really Just Benign? Peter R Eby, MD, FSBI Virginia Mason Medical Center Seattle, WA

Journal of Breast Cancer

Table 1. Classification of US Features Based on BI-RADS for US in Benign and Malignant Breast Lesions US Features Benign n(%) Malignant n(%) Odds

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Ductal carcinoma in situ, underestimation, ultrasound-guided core needle biopsy

BREAST MRI. Elizabeth A. Rafferty, M.D. Avon Comprehensive Breast Center Massachusetts General Hospital Harvard Medical School

BREAST MRI. Elizabeth A. Rafferty, M.D. Avon Comprehensive Breast Center Massachusetts General Hospital Harvard Medical School

Patient Outcomes in Canceled MRI-Guided Breast Biopsies

Management of Palpable Abnormalities in the Breast Katerina Dodelzon, MD July 31, 2018, 7:00pm ET

Current Status of Supplementary Screening With Breast Ultrasound

When do you need PET/CT or MRI in early breast cancer?

Computer-Aided Evaluation of Malignancy with Magnetic Resonance Imaging of the Breast. Original Policy Date

Pitfalls and Limitations of Breast MRI. Susan Orel Roth, MD Professor of Radiology University of Pennsylvania

ORIGINAL PAPER. Background parenchymal enhancement in preoperative breast MRI

Aims and objectives. Page 2 of 10

Second-look ultrasonography for MRI-detected suspicious breast lesions in patients with breast cancer

Contrast-enhanced magnetic resonance imaging (MRI) is a complementary

ACRIN 6666 IM Additional Evaluation: Additional Views/Targeted US

Newly Diagnosed Breast Cancer: Preoperative Imaging and Localization

MEDICAL POLICY SUBJECT: MAGNETIC RESONANCE IMAGING (MRI) OF THE BREAST. POLICY NUMBER: CATEGORY: Technology Assessment

BI-RADS and Breast MRI. Kathy Borovicka, M.D. Thursday February 15, 2018

Mammographic imaging of nonpalpable breast lesions. Malai Muttarak, MD Department of Radiology Chiang Mai University Chiang Mai, Thailand

Detailed Program of the second BREAST IMAGING AND INTERVENTIONS PROGRAM am am : Clinician s requirements from breast imaging

Computer-Aided Evaluation of Malignancy with Magnetic Resonance Imaging of the Breast

Vacuum-assisted breast biopsy using computer-aided 3.0 T- MRI guidance: diagnostic performance in 173 lesions

Rate of Malignancy in MRI-Detected Probably Benign (BI-RADS 3) Lesions

Atypical ductal hyperplasia diagnosed at ultrasound guided biopsy of breast mass

J Clin Oncol 26: by American Society of Clinical Oncology INTRODUCTION

E94. Aims and Objectives To assess whether it is possible to establish. received revised accepted

Non-mass Enhancement on Breast MRI. Aditi A. Desai, MD Margaret Ann Mays, MD

Lesion Imaging Characteristics Mass, Favoring Benign Circumscribed Margins Intramammary Lymph Node

Clinical Practice Guideline for the Indications for Use of Breast Magnetic Resonance Imaging (MRI)

Triple-negative breast cancer: which typical features can we identify on conventional and MRI imaging?

Imaging the Symptomatic Patient. Avice M.O Connell MD,FACR,FSBI Professor of Imaging Sciences Director, Women s Imaging University of Rochester

BR 1 Palpable breast lump

Radiologic Findings of Mucocele-like Tumors of the breast: Can we differentiate pure benign from associated with high risk lesions?

Angela Gilliam, MD University of Colorado Surgical Grand Rounds November 3, 2008

Triple Negative Breast Cancer

Here are examples of bilateral analog mammograms from the same patient including CC and MLO projections.

Feasibility of MRI-guided large-core-needle biopsy of suspiscious breast lesions at 3T

Impact of value based breast cancer care pathway implementation on pre-operative breast magnetic resonance imaging utilization

What the surgeon wants from the radiologist before breast cancer surgery. Erica Patocskai Isabelle Trop

Date of Preparation: December 8, 2017 A. GENERAL INFORMATION. 1. Name: Eun Sook KO Citizenship: Republic of Korea

How to Use MRI Following Neoadjuvant Chemotherapy (NAC) in Locally Advanced Breast Cancer

Mammographically non-calcified ductal carcinoma in situ: sonographic features with pathological correlation in 35 patients

AMSER Case of the Month: September 2018

Spiculated breast masses on MRI: Which category should we choose, 4 or 5?

Correlation Between BIRADS Classification and Ultrasound -guided Tru-Cut Biopsy Results of Breast Lesions: Retrospective Analysis of 285 Patients

SBI/ACR Breast Imaging Symposium April 7-10, 2016 Austin, TX

MP Magnetic Resonance Imaging for Detection and Diagnosis of Breast Cancer

BREAST MRI. VASILIKI FILIPPI RADIOLOGIST CT MRI & PET/CT Departments Hygeia Hospital, Athens, Greece

MEDICAL POLICY SUBJECT: MAMMOGRAPHY: COMPUTER- AIDED DETECTION (CAD) POLICY NUMBER: CATEGORY: Technology Assessment

ACR Appropriateness Criteria on Nonpalpable Mammographic Findings (Excluding Calcifications)

Breast MRI: Friend or Foe?

RSNA, /radiol Appendix E1. Methods

BARC/2013/E/019 BARC/2013/E/019. AUDIT OF MAMMOGRAPHY PERFORMED IN OUR HOSPITAL by Surita Kantharia Medical Division

Breast Pathology in Men: Radiologic-Pathologic Correlation

Role of PEM in Breast Cancer Management. Judy Kalinyak, MD, PhD Chief Medical Officer Naviscan, Inc (San Diego, CA)

CDIS: what's beyond microcalcifications? - Pictorial essay

PLACE LABEL HERE. ACRIN 6657 MRI Form: Pre-Treatment (MRI-1)

MR Imaging of the Ipsilateral Breast in Women with Percutaneously Proven Breast Cancer

MRI Occult Invasive Breast Cancer

Introduction ORIGINAL ARTICLE. 170 Ultrasonography 33(3), July 2014 e-ultrasonography.org

BI-RADS CATEGORIZATION AND BREAST BIOPSY categorization in the selection of appropriate breast biopsy technique is also discussed. Patients and method

MRI BI-RADS: How to make it out?

Title: Ultrasound for Breast Cancer Screening: Clinical Effectiveness. Date: 4 January Context and policy issues:

Role of positron emission mammography (PEM) for assessment of axillary lymph node status in patients with breast cancer

Case series: imaging features of intraductal papillomas in patients presenting as nipple discharge

EVALUATION OF AXILLARY LYMPH NODES AFTER NEOADJUVANT SYSTEMIC THERAPY KIM, MIN JUNG SEVERANCE HOSPITAL, YONSEI UNIVERSITY

Case study 1. Rie Horii, M.D., Ph.D. Division of Pathology Cancer Institute Hospital, Japanese Foundation for Cancer Research

Mammographic evaluation of palpable breast masses with pathological correlation: a tertiary care centre study in Nepal

Multicenter Evaluation of the Breast Lesion Excision System, a Percutaneous, Vacuum-Assisted, Intact-Specimen Breast Biopsy Device

Breast Cancers Not Detected at MRI: Review of False-Negative Lesions

Pathologic outcomes of coarse heterogeneous calcifications detected on mammography

Emerging Techniques in Breast Imaging: Contrast-Enhanced Mammography and Fast MRI

Underestimation of Atypical Ductal Hyperplasia at Sonographically Guided Core Biopsy of the Breast

MR sin plass i brystkreftdiagnostikk, dagens anbefalinger og fremtidsperspektiver

Breast Magnetic Resonance Imaging Indications in Current Practice

Evaluation of BI-RADS 3 lesions in women with a high risk of hereditary breast cancer.

Successful Breast MRI Program : The ingredients

BI-RADS Categorization As a Predictor of Malignancy 1

Breast MR biopsy. I Thomassin-Naggara, A.Jalaguier-Coudray, J Chopier

MEDICAL IMAGING AND BREAST DISEASE HOW CAN WE HELP YOU?

Does elastography change the indication to biopsy? IBDC

Correlation between lesion type and the additional value of digital breast tomosynthesis

PLACE LABEL HERE BASELINE / PRE-TREATMENT. ACRIN 6657 Extension MRI Form: Baseline / Pre-Treatment MRI 1. o Unknown

Magnetic resonance imaging (MRI) in high risk women: benefits and problems

Monitoring neo-adjuvant chemotherapy: comparison of contrast-enhanced spectral mammography (CESM) and MRI versus breast cancer characteristics

Invasive lobular carcinoma of the breast; spectrum of imaging findings.

BREAST IMAGING and NEW IMAGING MODALITIES- A Surgeons view

Radiologic and pathologic correlation of non-mass like breast lesions on US and MRI: Benign, high risk, versus malignant

Radiologic and pathologic correlation of non-mass like breast lesions on US and MRI: Benign, high risk, versus malignant

DCIS of the Breast--MRI findings with mammographic correlation.

Study on Efficacy of Preoperative Ultrasonography for Axillary Lymph Node Involvement In Breast Carcinoma

ISSN X (Print) Research Article. *Corresponding author Dr. Amlendu Nagar

Pharmacokinetic evaluation of DCIS

Leonard M. Glassman MD

Transcription:

Correlation between MRI & biopsies under second look Ultrasound Anne de Roquancourt, Service d anatomopathologie Cédric de Bazelaire, Service de radiologie Hôpital Saint-Louis Paris

Introduction Correlation between MRI & biopsies under second look US 2

CMS Saint-Louis Retrospective study 100 patients 2008 2009 2 nd look US + Biopsy Follow-up 2-4 years 3

Displacement? Correlation between MRI & biopsies under second look US 4

Switch MRI Utrasound Displacement of the target High in anterior-posterior axis: 30 à 60 mm 1 (K=0.55) Moderate in other axis : 10 mm 1 5 1. Carbonaro LA. Eur J Radiol. 2012

Displacement Breast cancer history, new microcalcifications of the left lower External Quadrant BIRADS 4. 6

Displacement MPR provides good showing of the distances between the lesion and the skin/muscle/scar 7

Agreement between MRI and US Location of the target Anteror/posterior displacement Fisher, p= 0.55 Cranio caudal displacement Quadrant Superior/lower: Kappa=0.97 Lateral displacement Quadrant Internal/External : Kappa=0.93 The hour topography Kappa=0.52 8

Displacement MIP provides good showing of the location of the lesions 9

Morphological findings Correlation between MRI & biopsies under second look US 10

Agreement between MRI and US Morphological findings Shape: benign vs suspicious Kappa=0.09 Margin: benign vs suspicious Kappa=0.23 Size T-test, p=0.0001 BIRADS 3 vs 4 &5 Kappa=0.11 11

Agreement between MRI and US: morphological findings 46 yo, history of breast cancer 12 1. Houssami N. J Clin Oncol Off J Am Soc Clin Oncol. 2008

Agreement between MRI and US: morphological findings 46 yo, history of breast cancer 13 1. Houssami N. J Clin Oncol Off J Am Soc Clin Oncol. 2008

Pathology IDC SBR grade 1 14

Succes rate according morphological findings Correlation between MRI & biopsies under second look US 15

Success rate of second look US: Mass versus non-mass 60 yo, staging of ILC of the right breast 63 yo, history of breast cancer, follow-up 16

Success rate of second look US: Mass versus non-mass 60 yo, staging of ILC of the right breast 63 yo, history of breast cancer, follow-up 17 1. LaTrenta LR. Radiology. 2003; 2. Trop I. Current problems in diagnostic radiology. 2010; 3. Wiratkapun C. Acad Radiol. 2008; 4. Meissnitzer M. Am J Roentgenol. 2009

Pathology Dystrophy: adenosis Scare sclerosis 18

Success rate of second look US: Suspicions versus benign 60 yo, left nipple retraction 57 yo, history of breast cancer, lymph nodes in left axilla 19 1. Wiratkapun C. Acad Radiol. 2008; 2. Meissnitzer M. Am J Roentgenol. 2009

Success rate of second look US: Suspicions versus benign 60 yo, left nipple retraction 57 yo, history of breast cancer, lymph nodes in left axilla 20 1. Wiratkapun C. Acad Radiol. 2008; 2. Meissnitzer M. Am J Roentgenol. 2009

Pathology Desmoïde fibroma IDC, SBR grade II Arrighi 1698028093 * H0907873 21

Succes rate according to the size Size Masses Non-Masses <5 mm 50%? 5-10 mm 56% 13% 10-15 mm 72% 25% >15 mm 86% 42% 22 1. Meissnitzer M. Am J Roentgenol. 2009

Depth Correlation between MRI & biopsies under second look US 23

Breast cancer risk according depth Chi2, p=0,066 24

Breast cancer risk according depth 45 yo, left breast cancer staging 25 1. Houssami N. J Clin Oncol Off J Am Soc Clin Oncol. 2008

Breast cancer risk according depth 45 yo, left breast cancer staging 26 1. Houssami N. J Clin Oncol Off J Am Soc Clin Oncol. 2008

Pathology IDC SBR grade II 27

Cancer rates according to risk factor Correlation between MRI & biopsies under second look US 28

Cancer rate according to risk factors High risk versus no risk patient Fisher test, p=0.79 History of breast cancer in young patient Fisher, p=0.34 During staging Fisher, p=0.80 Be careful with suspicious Clinical findings 29

Risk factors 37 yo, BRCA1 mutation, history of right breast cancer, screening 30

Risk factors 37 yo, BRCA1 mutation, history of right breast cancer, screening 31

Risk factors 37 yo, BRCA1 mutation, history of right breast cancer, screening 32

Pathology Fibrous dystrophy 33

Cancer rates according to morphological findings in MRI Correlation between MRI & biopsies under second look US 34

Suspicious findings in MRI Mass Margins: NPV = 0.86 (Fisher test, p=0.03) Enhancement curves: NPV = 1 (Fisher test, p=0.01) T1, T2, Shape, internal enhancement : (Fisher test, p>0.072) Size (Student s t-test, p = 0.89). Non-Mass Distribution, internal enhancement: NPV < 0.85 (Fisher test, p>0.56) BIRADS BIRADS 3 : NPV = 0.94 (Fisher, p=0,068) 35

Enhancement curves 69 yo, breast cancer metastasis in axillary lymph nodes 36

Enhancement curves 69 yo, breast cancer metastasis in axillary lymph nodes 37

Enhancement curves 69 yo, breast cancer metastasis in axillary lymph nodes 38

Pathology IDC SBR grade III Triple negative Milagre, 2608014304 H0806358 39

Cancer rates according to morphological findings in US Correlation between MRI & biopsies under second look US 40

Suspicious findings in US Shape: NPV = 0.90 (Fisher, p=0.025) Margin: NPV = 0.91 (Fisher, p=0,0046) Orientation: NPV = 0.87 (Fisher, p=0,0018) Depth, echogenicity, posterior US Beam (Fisher, p=0,53) Taille : t-test, p=0,65 BIRADS : NPV = 0.95%, (Fisher, p=0,039) 41

Vertical orientation 44 yo, discrepancy between luminal breast cancer and triple negative lymph node metastasis 42

Vertical orientation 44 yo, discrepancy between luminal breast cancer and triple negative lymph node metastasis 43

Vertical orientation 44 yo, discrepancy between luminal breast cancer and triple negative lymph node metastasis 44

Vertical orientation 44 yo, discrepancy between luminal breast cancer and triple negative lymph node metastasis 45

Pathology IDC SBR Grade III Inflammatory stroma 46

Conclusion Correlation between MRI & biopsies under second look US 47

Take Home Messages Risk factors were not reliable criteria for establishing an indication for second look ultrasound Displacement in anterior-posterior axis Masses are found more frequently than non-mass BIRADS 5 are found more frequently than BIRADS 4 Circumscribed contours and a progressive enhancement curve for masses on MRI had the strongest NPV (>0.85) Round or oval shape, circumscribed contours and the parallel orientation on US had the strongest NPV (>0.85) Correlation between abnormalities detected on MRI and US is sometimes delicate, biopsy and clip placement should be easily recommended 48

49

Litterature review 1. Houssami N, Ciatto S, Macaskill P, Lord SJ, Warren RM, Dixon JM, et al. Accuracy and surgical impact of magnetic resonance imaging in breast cancer staging: systematic review and meta-analysis in detection of multifocal and multicentric cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2008 Jul 1;26(19):3248 58. 2. Monticciolo DL. Postbiopsy Confirmation of MR-Detected Lesions Biopsied Using Ultrasound. Am J Roentgenol. 2012 Jun;198(6):W618 W620. 3. Carbonaro LA, Tannaphai P, Trimboli RM, Verardi N, Fedeli MP, Sardanelli F. Contrast enhanced breast MRI: Spatial displacement from prone to supine patient s position. Preliminary results. Eur J Radiol. 2012 Jun;81(6):e771 e774. 4. LaTrenta LR, Menell JH, Morris EA, Abramson AF, Dershaw DD, Liberman L. Breast lesions detected with MR imaging: utility and histopathologic importance of identification with US. Radiology. 2003 Jun;227(3):856 61. 5. Berg WA, Blume JD, Cormack JB, Mendelson EB, Madsen EL. Lesion detection and characterization in a breast US phantom: results of the ACRIN 6666 Investigators. Radiology. 2006 Jun;239(3):693 702. 6. Trop I, Labelle M, David J, Mayrand MH, Lalonde L. Second-look targeted studies after breast magnetic resonance imaging: practical tips to improve lesion identification. Current problems in diagnostic radiology. 2010 Sep;39:200 11. 7. Wiratkapun C, Duke D, Nordmann AS, Lertsithichai P, Narra V, Barton PT, et al. Indeterminate or suspicious breast lesions detected initially with MR imaging: value of MRI-directed breast ultrasound. Acad Radiol. 2008 May;15(5):618 25. 8. Meissnitzer M, Dershaw DD, Lee CH, Morris EA. Targeted Ultrasound of the Breast in Women With Abnormal MRI Findings for Whom Biopsy Has Been Recommended. Am J Roentgenol. 2009 Oct;193(4):1025 9. 9. Abe H, Schmidt RA, Shah RN, Shimauchi A, Kulkarni K, Sennett CA, et al. MR-Directed ( Second-Look ) Ultrasound Examination for Breast Lesions Detected Initially on MRI: MR and Sonographic Findings. Am J Roentgenol. 2010 Feb;194(2):370 7. 10. Sim LSJ, Hendriks JHCL, Bult P, Fook-Chong SMC. US correlation for MRI-detected breast lesions in women with familial risk of breast cancer. Clin Radiol. 2005 Jul;60(7):801 6. 11. Fiaschetti V, Salimbeni C, Gaspari E, Dembele GK, Bolacchi F, Cossu E, et al. The role of second-look ultrasound of BIRADS-3 mammary lesions detected by breast MR imaging. Eur J Radiol. 2012 Nov;81(11):3178 84. 12. Trop I, David J, Lalonde L. Postbiopsy confirmation of adequate targeting after second-look biopsy of MRI-enhancing breast lesions. Ajr Am J Roentgenol. 2013 Jan;200(1):W93. 13. Elshof LE, Rutgers EJT, Deurloo EE, Loo CE, Wesseling J, Pengel KE, et al. A practical approach to manage additional lesions at preoperative breast MRI in patients eligible for breast conserving therapy: results. Breast Cancer Res Treat. 2010 Jul 22;124(3):707 15. 14. Holland R, Hendriks JH, Vebeek AL, Mravunac M, Schuurmans Stekhoven JH. Extent, distribution, and mammographic/histological correlations of breast ductal carcinoma in situ. Lancet. 1990 Mar 3;335:519 22. 15. Sardanelli F, Boetes C, Borisch B, Decker T, Federico M, Gilbert FJ, et al. Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group. Eur J Cancer. 2010 May;46:1296 316. 16. Nakano S, Kousaka J, Fujii K, Yorozuya K, Yoshida M, Mouri Y, et al. Impact of real-time virtual sonography, a coordinated sonography and MRI system that uses an image fusion technique, on the sonographic evaluation of MRI-detected lesions of the breast in second-look sonography. Breast Cancer Res Treat. 2012 Jul 24;134(3):1179 88. 50

Pathology Correlation between MRI & biopsies under second look US 51

Pathology 52

Fibrosis changes 59 yo, history of right breast cancer, right nipple retraction 46 yo, BRCA 2, history of breast cancer, follow up 53

Fibrosis changes 59 yo, history of right breast cancer, right nipple retraction 46 yo, BRCA 2, history of breast cancer, follow up 54

Pathology Fibrous Dystophy Fibrosis, nuclear dystrophy post radiotherapy SARRAZY, 1395075632 H0803558 Margot, 2406009682 H0911855 55

MRI Findings 44 yo, staging of a right breast cancer 53 yo, distorsion in the upper quadrants of the left breast 56

MRI Findings 44 yo, staging of a right breast cancer 53 yo, distorsion in the upper quadrants of the left breast 57

Pathology Fibrous Dystophy Dystrophy with atypical ductal hyperplasia De Saint Ours, 2608044316 H0815874 PASSAS, 1191336321 H0911439 58